Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977809 | 0.92 | TSHR (0.36) | TSHRCD274KMT2AALDH1A1THRB | |
| SCHEMBL3066933 | 0.91 | CNR1 (0.37) | TSHRKMT2AALDH1A1RORCLMNA | |
| SCHEMBL3050707 | 0.90 | CD274 (0.35) | CD274KMT2AALDH1A1RORCPDCD1 | |
| SCHEMBL2974146 | 0.88 | OPRM1 (0.41) | TSHRCD274LMNAPDCD1OPRM1 | |
| SCHEMBL2969355 | 0.88 | KMT2A (0.36) | CD274KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL841746 | 0.85 | AGTR1 (0.37) | TSHRKMT2AALDH1A1RORC | |
| SCHEMBL841745 | 0.85 | AGTR1 (0.37) | TSHRKMT2AALDH1A1RORC | |
| SCHEMBL3066934 | 0.84 | ALOX5AP (0.33) | RORCIDH1CNR1ALOX5APFEN1 | |
| SCHEMBL2967736 | 0.84 | BDKRB1 (0.40) | CD274PDCD1OPRM1OPRK1ALOX5AP | |
| SCHEMBL2977804 | 0.82 | PTGES (0.36) | TSHRKMT2AALDH1A1LMNACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011597-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8735625-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140046075-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8394846-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120129900-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20100267788-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267788-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | TSHR 286/4885CD274 4705/4885KMT2A 3360/4885 |
| US-20150011597-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | TSHR 286/4885CD274 4705/4885KMT2A 3360/4885 |
| US-20140046075-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | TSHR 286/4885CD274 4705/4885KMT2A 3360/4885 |
| US-20120129900-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | TSHR 286/4885CD274 4705/4885KMT2A 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.